ArticleScientific reports2023
Molecular and virulence characteristics of carbapenem-resistant Acinetobacter baumannii isolates: a prospective cohort study.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Antibacterial and anti-biofilm mechanisms of 1,8-cineole against colistin-resistant Acinetobacter baumannii: an integrated in vitro, gene expression, and in silico study.Scientific reports · 2026Article
- Molecular analysis of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Peptide-based antimicrobial effect against carbapenem-resistantFrontiers in pharmacology · 2026Article
- Therapeutic challenges and emerging strategies against carbapenem-resistantCurrent research in microbial sciences · 2026Review
- High Prevalence of Virulence andPathogens (Basel, Switzerland) · 2025Article
- Natural compounds for colistin-resistant Acinetobacter baumannii biofilm control: eugenol, cinnamaldehyde, and carvacrol.Molecular biology reports · 2025Article
- Comparative effectiveness and safety of colistin-based versus high-dose ampicillin/sulbactam-based combination therapy for nosocomial pneumonia caused by carbapenem-resistantAntimicrobial agents and chemotherapy · 2025Article
- Distribution patterns and evolution of antimicrobial resistance in Gram-negative bacteria within the intensive care unit of a tertiary hospital from 2019 to 2024.Frontiers in microbiology · 2025Article
- Article
- The fitness connection of antibiotic resistance.Frontiers in microbiology · 2025Article
- Molecular characterization of carbapenem-resistant and carbapenem-sensitiveFrontiers in microbiology · 2025Article
- Investigation and control of a suspected outbreak of carbapenem-resistantFrontiers in public health · 2025Article
- The Microbiological Characteristics ofOpen forum infectious diseases · 2024Article
- Co-production of metallo-β-lactamase and OXA-type β-lactamases in carbapenem-resistant Acinetobacter baumannii clinical isolates in North East India.World journal of microbiology & biotechnology · 2024Article
- Molecular Epidemiology and Genetic Characterization of Carbapenem-ResistantInfection and drug resistance · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to characterize the molecular features and virulence profiles of carbapenem-resistant Acinetobacter baumannii (CRAB) isolates. Clinical CRAB isolates were obtained from blood cultures of adult patients with CRAB bacteremia, collected between July 2015 and July 2021 at a Korean hospital. Real-time polymerase chain reaction was used to detect 13 virulence genes, genotyping was conducted via multilocus sequence typing (MLST), and a Tenebrio molitor infection model was selected for survival analysis. Herein, 170 patients, from whom CRAB isolates were collected, showed the in-hospital mortality rate of 57.6%. All 170 clinical CRAB isolates harbored bla
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.